KDR and Alzheimer disease: To overcome these unmet needs, such as novel therapeutics based on the etiology of AD, we developed an acetylated tetrapeptide (N-acetyl-Arg-Leu-Tyr-Glu, hereafter Ac-RLYE) that selectively targets VEGFR-2 signaling, which is closely associated with increased vascular permeability.